Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α_West China Medical Journal

Authors：

Department of Infectious Diseases, the First People’s Hospital of Yibin City, Yibin Sichuan 644000, China;

Corresponding?author：

Keywords：

α干擾素; HBeAg(+); 慢性乙型肝炎; 病毒學; 血清學

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:觀察α干擾素治療HBeAg(+)慢性乙型肝炎患者過程中病毒學及血清學動態變化情況,通過早期療效預測終末療效。方法:觀察144例HBeAg(+)慢性乙型肝炎患者經α干擾素治療24WK及隨訪24WK 過程中HBV-DNA以及HBeAg變化情況.結果:經α干擾素治療12、24、48WK時,HBV-DNA下降到可檢測值以下病例數分別為32、32、31例;同期HBeAg發生血清轉換病例數分別為16、17、21例。結論:干擾素治療12WK時患者病毒學及血清學結果可早期預測終末療效。

Citation： ZHENG Yongli.. Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α. West China Medical Journal, 2009, 24(9): 2334-2335. doi: Copy

1.	INADA M, YOKOSUKA O. Current antiviral therapies for chronic hepatitis B[J]. Hepatol Res, 2008, 38(6):535-42.
2.	PLANAS R, MORILLAS R M. Treatment of hepatitis B virus infection: present and future[J]. Gastroenterol Hepatol,2008, 31(6):349-355.
3.	RAMOSBELLO D, RAMOSNIEMBRO F. A review of interferons: fifty years later (19572007)[J]. Gac Med Mex,2008,144(1):55-65.
4.	THOMAS H C, KARAYIANNIS P, BROOK G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon[J]. J Hepatol,1991;13 Suppl 1:S4-7.
5.	RUIZMORENO M, CAMPS T, JIMENEZ J, et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B[J].J Hepatol,1995 May;22(5):540-4.
6.	TER BORG M J, VAN ZONNEVELD M, ZEUZEM S, et al. Patterns of viral decline during PEGinterferon α2b therapy in HBeAgpositive chronic hepatitis B: relation to treatment response[J]. Hepatology, 2006 Sep;44(3):721-7.
7.	VAN DER EIJK A A, NIESTERS H G, HANSEN B E, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBeantigen positive hepatitis B patients treated with interferonα[J]. J Viral Hepat, 2006 Feb;13(2):96-103.

1. INADA M, YOKOSUKA O. Current antiviral therapies for chronic hepatitis B[J]. Hepatol Res, 2008, 38(6):535-42.
2. PLANAS R, MORILLAS R M. Treatment of hepatitis B virus infection: present and future[J]. Gastroenterol Hepatol,2008, 31(6):349-355.
3. RAMOSBELLO D, RAMOSNIEMBRO F. A review of interferons: fifty years later (19572007)[J]. Gac Med Mex,2008,144(1):55-65.
4. THOMAS H C, KARAYIANNIS P, BROOK G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon[J]. J Hepatol,1991;13 Suppl 1:S4-7.
5. RUIZMORENO M, CAMPS T, JIMENEZ J, et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B[J].J Hepatol,1995 May;22(5):540-4.
6. TER BORG M J, VAN ZONNEVELD M, ZEUZEM S, et al. Patterns of viral decline during PEGinterferon α2b therapy in HBeAgpositive chronic hepatitis B: relation to treatment response[J]. Hepatology, 2006 Sep;44(3):721-7.
7. VAN DER EIJK A A, NIESTERS H G, HANSEN B E, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBeantigen positive hepatitis B patients treated with interferonα[J]. J Viral Hepat, 2006 Feb;13(2):96-103.

West China Medical Journal

Clinical Characteristics of Dynamic in the Treatment of HBeAg Postive Chronic Hepatitis B with IFN-α

Abstract Full text Figures/Tables Video References Cited by

Format

Content